Abstract
Treatment of neonatal hyperbilirubinemia is usually based on the measurements of total serum bilirubin levels. Based on empirical data, it is generally recommended to start phototherapy at lower levels in low birth weight and very low birth weight infants than in term infants, but no general agreement exists on exact limits. Treatment criteria in preterm infants do not, however, have the same empirical backing as in term infants. The very low and extremely low birth weight infants are more susceptible to bilirubin toxicity. However, bilirubin may function as an antioxidant and enzyme inducer in these infants. Several other different approaches to establish treatment criteria have also been suggested, and a summary of these are presented and discussed. With the exception of measurement of unbound bilirubin, very few of these approaches have been validated in routine clinical settings. However, unbound bilirubin is at present mainly used also as a parameter to be evaluated in relation to total bilirubin values. The present treatment criteria result in a considerable overtreatment particularly of term infants. However, with a more relaxed attitude toward neonatal hyperbilirubinemia by health care professionals, kernicterus is again reported in term infants. Because the basic mechanisms of bilirubin toxicity as well as the relative significance of the maximum serum bilirubin level compared to the duration of hyperbilirubinemia are not known, individual assessment of a newborn infant's tolerance for hyperbilirubinemia is difficult. Major changes in the empirically developed criteria for treatment of hyperbilirubinemia in the newborn are therefore not justified in the near future. For term infants, the search for validated criteria for follow-up of jaundiced infants after discharge are therefore more important than revision of existing criteria for phototherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Maisels MJ Bilirubin. On understanding and influencing its metabolism in the newborn infant Pediatr Clin N Am 1972 19 447
Jährig K, Jährig L, Meisel P. (eds) Phototherapy. Treating Neonatal Jaundice with Visible Light Munich: Quintessenz Verlag 1993
Maisels MJ Clinical studies on the sequelae of hyperbilirubinemia In Levine RL, Maisels MJ, editors. Hyperbilirubinemia in the Newborn. Report of the 85th Ross Conference on Pediatric Research. Columbus, Ohio 1983 p. 26–38
Bhutani VK, Gourley GR, Adler S, Kreamer B, et al Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia Pediatrics 2000 106 e17
Tayaba R, Gribetz D, Gribetz I, Holzman IR Noninvasive estimation of serum bilirubin Pediatrics 1998 102 e28
Americam Academy of Pediatrics Practice Parameter: Management of hyperbilirubinemia in the healthy term newborn Pediatrics 1994 94 558
Johnson L, Bhutani K Guidelines for management of the jaundiced term and near-term infant Clin Perinatol 1998 25 555
Hansen TWR Therapeutic approaches to neonatal jaundice. An international survey Clin Pediatr 1996 35 309
Cashore WJ Bilirubin and jaundice in the micropremie Clin Perinatol 2000 27 171
Bratlid D How bilirubin gets into the brain Clin Perinatol 1990 17 449
Nakamura H, Yonetani M, Uetani Y, Funato M, et al Determination of unbound bilirubin for prediction of kernicterus in low birthweight infants Acta Paediatr Jpn 1992 34 642
Cashore WJ Bilirubin binding tests. In Levine RL, Maisels MJ, editors. Hyperbilirubinemia in the Newborn. Report of the 85th Ross Conference on Pediatric Research. Columbus, Ohio 1983 p. 101–10
Stevenson DK, Vreman HJ Carbon monoxide and bilirubin production in neonates Pediatrics 1997 100(2) 252
Slusher TM, Vreman HJ, McLaren DW, Stevenson DK Carboxyhemoglobin predicts bilirubin-related morbidity and mortality in infants Pediatr Res 1993 33 237A
Funato M, Tamai H, Shimada S, Nakamura H Vigintiphobia, unbound bilirubin, and brainstem responses Pediatrics 1994 93 50
Vohr BR New approaches to assessing the risks of hyperbilirubinemia Clin Perinatol 1990 17 293
Brodersen R Prevention of kernicterus, based on recent progress in bilirubin chemistry Acta Paediatr Scand 1977 66 625
Bratlid D Bilirubin toxicity: pathophysiology and assessment of risk factors NY State J Med 1991 91 489
Rubaltelli FF Current drug treatment options in neonatal hyperbilirubinemia and the prevention of kernicterus Drugs 1998 56 23
Watchko JF, Daood MJ, Hansen TW Brain bilirubin content is increased in P-glycoprotein-deficient transgenic null mice Pediatr Res 1998 44 763
Newman TB, Maisels MJ Evaluation and treatment of jaundice in the term newborn: A kinder, gentler approach Pediatrics 1992 89 809
Seidman DS, Moise J, Ergaz Z, Laor A, et al A new blue light-emitting phototherapy device: A prospective randomized controlled study J Pediatr 2000 136 771
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bratlid, D. Criteria for Treatment of Neonatal Jaundice. J Perinatol 21 (Suppl 1), S88–S92 (2001). https://doi.org/10.1038/sj.jp.7210656
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jp.7210656
This article is cited by
-
Kernicterus as a ‘never-event’: A newborn safety standard?
The Indian Journal of Pediatrics (2005)